Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses Article Swipe
Related Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Virology
Coronavirus disease 2019 (COVID-19)
Titer
Food and drug administration
2019-20 coronavirus outbreak
Convalescent plasma
Medicine
Pandemic
Virus
Pharmacology
Infectious disease (medical specialty)
Internal medicine
Disease
Outbreak
Yi-Chan Lin
,
David H. Evans
,
Ninette F. Robbins
,
Guillermo Orjuela
,
Queenie Hu
,
Reuben Samson
,
Kento T. Abe
,
Bhavisha Rathod
,
Karen Colwill
,
Anne‐Claude Gingras
,
Ashleigh R. Tuite
,
Qilong Yi
,
Sheila F. O’Brien
,
Steven J. Drews
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1128/spectrum.02811-22
· OA: W4296782706
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1128/spectrum.02811-22
· OA: W4296782706
The United States Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of COVID-19 convalescent plasma (CCP) to treat hospitalized patients with COVID-19 in August 2020. However, by 4 February 2021, the FDA had revised the convalescent plasma EUA.
Related Topics
Finding more related topics…